Log In
BCIQ
Print this Print this
 

OSI-930

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionDual receptor tyrosine kinase c-Kit/VEGFR inhibitor
Molecular Target Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionStem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerSimcere Pharmaceutical Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/26/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today